title: Survivorship: cognitive function, version 1.2014.
abstract: Cognitive impairment is a common complaint among cancer survivors and may be a consequence of the tumors themselves or direct effects of cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over the long term and, when more severe, can impact quality of life and function. This section of the NCCN Guidelines for Survivorship provides assessment, evaluation, and management recommendations for cognitive dysfunction in survivors. Nonpharmacologic interventions (eg, instruction in coping strategies; management of distress, pain, sleep disturbances, and fatigue; occupational therapy) are recommended, with pharmacologic interventions as a last line of therapy in survivors for whom other interventions have been insufficient.
authors.forename: Crystal S
authors.initials: CS
authors.lastname: Denlinger
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Ligibel
authors.forename: Madhuri
authors.initials: M
authors.lastname: Are
authors.forename: K Scott
authors.initials: KS
authors.lastname: Baker
authors.forename: Wendy
authors.initials: W
authors.lastname: Demark-Wahnefried
authors.forename: Debra L
authors.initials: DL
authors.lastname: Friedman
authors.forename: Mindy
authors.initials: M
authors.lastname: Goldman
authors.forename: Lee
authors.initials: L
authors.lastname: Jones
authors.forename: Allison
authors.initials: A
authors.lastname: King
authors.forename: Grace H
authors.initials: GH
authors.lastname: Ku
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Kvale
authors.forename: Terry S
authors.initials: TS
authors.lastname: Langbaum
authors.forename: Kristin
authors.initials: K
authors.lastname: Leonardi-Warren
authors.forename: Mary S
authors.initials: MS
authors.lastname: McCabe
authors.forename: Michelle
authors.initials: M
authors.lastname: Melisko
authors.forename: Jose G
authors.initials: JG
authors.lastname: Montoya
authors.forename: Kathi
authors.initials: K
authors.lastname: Mooney
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Morgan
authors.forename: Javid J
authors.initials: JJ
authors.lastname: Moslehi
authors.forename: Tracey
authors.initials: T
authors.lastname: O'Connor
authors.forename: Linda
authors.initials: L
authors.lastname: Overholser
authors.forename: Electra D
authors.initials: ED
authors.lastname: Paskett
authors.forename: Muhammad
authors.initials: M
authors.lastname: Raza
authors.forename: Karen L
authors.initials: KL
authors.lastname: Syrjala
authors.forename: Susan G
authors.initials: SG
authors.lastname: Urba
authors.forename: Mark T
authors.initials: MT
authors.lastname: Wakabayashi
authors.forename: Phyllis
authors.initials: P
authors.lastname: Zee
authors.forename: Nicole R
authors.initials: NR
authors.lastname: McMillian
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Freedman-Cass
mesh_terms: D000223:Adaptation, Psychological; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000628:therapy*; D005221:Fatigue / Q000628:therapy; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D000077408:Modafinil; D009788:Occupational Therapy; D059408:Pain Management; D011788:Quality of Life; D012893:Sleep Wake Disorders / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D064690:Wakefulness-Promoting Agents / Q000627:therapeutic use
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D064690:Wakefulness-Promoting Agents; D008774:Methylphenidate; D000077408:Modafinil